Latest Breaking News On - Richard ghalie - Page 1 : comparemela.com

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

David ursoRichard ghaliePharma incAcademic gi cancer consortiumClinical study protocolBevacizumab combinationInitial safetyInitial efficacy

MEI Pharma (MEIP) Reports Initial Data from Study of ME-344 in Combination with Bevacizumab

MEI Pharma (MEIP) Reports Initial Data from Study of ME-344 in Combination with Bevacizumab
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Davida walseyDavid ursoRichard ghalieMei pharma incPharma incAcademic gi cancer consortiumClinical study protocolBevacizumab combinationInitial safetyInitial efficacyPrivate securities litigation reform act

MEI Pharma (MEIP) Reports Update from Clinical Study of Voruciclib in Combination with Venetoclax

MEI Pharma (MEIP) Reports Update from Clinical Study of Voruciclib in Combination with Venetoclax
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesYesid alvarado valeroRichard ghalieDavida walseyDepartment of leukemiaUniversity of texas md anderson cancer centerSafety review committeePharma incMei pharma incAssociate professorCancer centerPlus venetoclax combinationInitial safetyInitial efficacyPrivate securities litigation reform act

MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

– Enrollment Initiated in 12-Patient Expansion Cohort Evaluating Voruciclib Plus Venetoclax in Ongoing Phase 1 Study – – Anti-leukemic Activity Across Multiple Heavily Pretreated Patients.

United statesRichard ghalieYesid alvarado valeroPharma incSafety review committeeDepartment of leukemiaUniversity of texas md anderson cancer centerAssociate professorCancer centerPlus venetoclax combinationInitial safetyInitial efficacy

MEI Pharma, Inc (NASDAQ:MEIP) Q4 2023 Earnings Call Transcript

MEI Pharma, Inc. (NASDAQ:MEIP) Q4 2023 Earnings Call Transcript September 26, 2023 MEI Pharma, Inc. beats earnings expectations. Reported EPS is $-2.4, expectations were $-3.25. Operator: Good day and welcome to the MEI Fiscal Year-End Earnings Call. My name is Gary and I will be the conference facilitator today. All participants will be in a […]

Yale jenDavid ursoStephen willeyRichard ghalieLaidlaw companyJay fileCable carAnnual stockholder meetingMovie studioNews media stocksDavid walseyDavid ursoRichard ghalieMei pharmaMay file